Fulgent Genetics (NASDAQ:FLGT) Issues FY25 Earnings Guidance

Fulgent Genetics (NASDAQ:FLGT) updated its FY25 earnings guidance on Friday. The company provided EPS guidance of $(0.65) for the period, compared to the consensus EPS estimate of ($0.15). The company issued revenue guidance of $310.0 million, compared to the consensus revenue estimate of $324.65 million. Fulgent Genetics also updated its FY 2025 guidance to -0.650–0.650 EPS.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the stock. StockNews.com cut shares of Fulgent Genetics from a “hold” rating to a “sell” rating in a research report on Wednesday, November 27th. Piper Sandler dropped their price target on shares of Fulgent Genetics from $26.00 to $22.00 and set a “neutral” rating for the company in a research report on Monday, November 11th.

Fulgent Genetics Stock Down 1.5 %

Shares of Fulgent Genetics stock opened at $15.45 on Friday. Fulgent Genetics has a 52-week low of $15.21 and a 52-week high of $25.11. The company has a 50 day moving average of $17.32 and a 200 day moving average of $19.46. The company has a market capitalization of $472.57 million, a P/E ratio of -2.80 and a beta of 1.39.

About Fulgent Genetics

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.